Company: CPMV
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001683168-25-002584
Chunk: 351

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1C
Chunk 351
---
 1,137,409
shares were available for future grants of share-based awards.

     F-19 

    Mosaic ImmunoEngineering, Inc.

    Notes to Consolidated Financial Statements
    For the Years Ended December 31, 2024 and 2023 (continued)

The cost of all share-based awards will be recognized
in the consolidated financial statements based on the fair value of the awards. The fair value of stock option awards will be determined
using the Black-Scholes valuation model on the date of grant. The fair value of restricted stock awards and RSUs will be equal to the
closing market price of our common stock on the date of grant. The Company will generally recognize share-based compensation expense over
the period of vesting or period that services will be provided for all time-based awards. Share-based compensation expense for the years
ended December 31, 2024 and 2023 was comprised of the following:

    Schedule of share-based compensation expense 

    Year Ended December 31, 2024  
    Year Ended December 31, 2023 
  
    Research and development 
    $4,867  
    $21,935 
  
    General and administrative 
     –  
     – 
  
    Total 
    $4,867  
    $21,935 

The following summarizes our transaction activity
related to RSUs for the year ended December 31, 2024:

    Schedule of RSU activity 

     Shares  
    Weighted Average Grant Date Fair Value 
  
    Nonvested at January 1, 2024 
     541,957  
    $3.01 
  
    Granted 
     –  
     – 
  
    Vested 
     –  
     – 
  
    Forfeited 
     (31,444) 
     (3.21)
  
    Nonvested at December 31, 2024 
     510,513  
    $3.00 

As of December 31, 2024, there was no unrecognized
compensation cost related to RSUs. As of December 31, 2024, 14,044 RSUs have vested under the 2020 Plan since its adoption.

10.        Income Taxes

The provision (benefit) for income taxes for the years ended December
31, 2024 and 2023 is